2008•European Journal of PharmacologyRequires access

The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice

Yusuke Moritoh, Koji Takeuchi, Tomoko Asakawa, Osamu Kataoka, Hiroyuki Odaka

Open publisher page 37 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 37 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Alogliptin, Pioglitazone, Internal medicine, Endocrinology, Dipeptidyl peptidase-4 inhibitor, Insulin, Thiazolidinedione, Type 2 diabetes

Back to paper search Browse research topics Original source

The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice — Research Paper | ScholarLens